| ID Source | ID |
|---|---|
| PubMed CID | 188321 |
| CHEMBL ID | 1683023 |
| SCHEMBL ID | 622623 |
| MeSH ID | M0070074 |
| Synonym |
|---|
| 6-chloropurine ribotide |
| 6-cl-purine ribotide |
| bdbm50222697 |
| chembl1683023 , |
| [(2r,3s,4r,5r)-5-(6-chloropurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate |
| 6-chloroinosine monophosphate |
| 6-chloropurine 9-beta-d-ribofuranosyl 5'-monophosphate |
| 6-chloropurine riboside 5'-monophosphate |
| 6-chloro-9-(5-o-phosphono-beta-d-ribofuranosyl)-9h-purine |
| SCHEMBL622623 |
| 6-chloropurine riboside 5'-phosphate |
| ALOBOMYIOYNCBS-KQYNXXCUSA-N |
| PD041621 |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Inosine-5'-monophosphate dehydrogenase 2 | Homo sapiens (human) | Ki | 62.0000 | 0.0060 | 0.1262 | 0.2600 | AID92483 |
| Inosine-5'-monophosphate dehydrogenase 1 | Homo sapiens (human) | Ki | 62.0000 | 0.0330 | 0.1654 | 0.3300 | AID92483 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| GMP biosynthetic process | Inosine-5'-monophosphate dehydrogenase 2 | Homo sapiens (human) |
| GTP biosynthetic process | Inosine-5'-monophosphate dehydrogenase 2 | Homo sapiens (human) |
| circadian rhythm | Inosine-5'-monophosphate dehydrogenase 2 | Homo sapiens (human) |
| lymphocyte proliferation | Inosine-5'-monophosphate dehydrogenase 2 | Homo sapiens (human) |
| cellular response to interleukin-4 | Inosine-5'-monophosphate dehydrogenase 2 | Homo sapiens (human) |
| 'de novo' XMP biosynthetic process | Inosine-5'-monophosphate dehydrogenase 2 | Homo sapiens (human) |
| GMP biosynthetic process | Inosine-5'-monophosphate dehydrogenase 1 | Homo sapiens (human) |
| GTP biosynthetic process | Inosine-5'-monophosphate dehydrogenase 1 | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID92483 | Inhibition of IMPDH (Inosine 5''-monophosphate dehydrogenase)from Escherichia coli B3 cells | 2003 | Bioorganic & medicinal chemistry letters, Feb-24, Volume: 13, Issue:4 | Inhibition of inosine monophosphate dehydrogenase (IMPDH) by 2-[2-(Z)-fluorovinyl]inosine 5'-monophosphate. |
| AID580010 | Inhibition of human IMPDH2 at 200 uM by SDS-PAGE in presence of 6 mM dithiothreitol | 2011 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 21, Issue:5 | Specific biotinylation of IMP dehydrogenase. |
| AID92484 | Inhibition of IMPDH (Inosine 5''-monophosphate dehydrogenase)from Escherichia coli B3 cells | 2003 | Bioorganic & medicinal chemistry letters, Feb-24, Volume: 13, Issue:4 | Inhibition of inosine monophosphate dehydrogenase (IMPDH) by 2-[2-(Z)-fluorovinyl]inosine 5'-monophosphate. |
| AID1646807 | Covalent binding affinity to Mycobacterium thermoresistibile IMPDH deltaCBS variant assessed as adduct formation at Cys341 by measuring 330 Da shift of increment in protein mass measured under denaturing conditions by ESI-MS spectral analysis | 2020 | Bioorganic & medicinal chemistry letters, 01-15, Volume: 30, Issue:2 | Covalent inactivation of Mycobacterium thermoresistibile inosine-5'-monophosphate dehydrogenase (IMPDH). |
| AID579907 | Ratio of Kinact to Ki for Escherichia coli IMPDH at 25 degC | 2011 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 21, Issue:5 | Specific biotinylation of IMP dehydrogenase. |
| AID579908 | Ratio of Kinact to Ki for human IMPDH2 at 25 degC | 2011 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 21, Issue:5 | Specific biotinylation of IMP dehydrogenase. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 6 (42.86) | 18.7374 |
| 1990's | 4 (28.57) | 18.2507 |
| 2000's | 2 (14.29) | 29.6817 |
| 2010's | 1 (7.14) | 24.3611 |
| 2020's | 1 (7.14) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 14 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||